The Impossibility of Informed Choice
Systemic, worldwide
Now
You want to take better care of your health. You search for a vitamin D supplement and find yourself facing tens of thousands of dietary supplement products on the U.S. market — nearly twenty times as many as in 1994, each competing for your attention. Multiple brands claim simultaneously to be "doctor recommended," "most bioavailable," and "clinically proven." You cannot evaluate these claims, because under the 1994 Dietary Supplement Health and Education Act, supplements require no pre-market FDA approval — the burden falls on the FDA to prove a product unsafe after it is already on the shelves, rather than on the manufacturer to demonstrate that it works before selling it. When independent laboratories actually test what is in the bottles, roughly one in five products fail on potency, identity, or contamination; 32% of multivitamins failed quality standards in ConsumerLab's 2026 review. In 2015, the New York Attorney General's DNA testing of store-brand herbal supplements at GNC, Target, Walmart, and Walgreens found that 79% of tests detected no DNA from the labeled plant or found contamination with other plant material — contaminants included rice, wheat, asparagus, and houseplants. The U.S. Preventive Services Task Force's 2022 review found "insufficient evidence" of benefit for most vitamin and mineral supplements, and a 2013 Annals of Internal Medicine editorial reviewing trials involving over 400,000 participants concluded that "most supplements do not prevent chronic disease or death, their use is not justified, and they should be avoided." The U.S. supplement industry's annual sales: $72.88 billion. The same problem confronts anyone trying to evaluate competing diet plans, exercise programs, skincare products, or any other domain where advertising claims flood the information space — every product presents itself as scientifically validated, and the actual evidence, where it exists, is buried beneath layers of marketing.
The pattern extends to everything that is sold. The United States and New Zealand are the only high-income countries that permit direct-to-consumer pharmaceutical advertising — more than $10 billion in 2024 alone. A 2023 study in JAMA found that 68% of the 135 top-selling prescription drugs were rated as offering low added benefit compared to existing alternatives — and that manufacturers devoted a larger share of their promotional budgets to consumer advertising for precisely those drugs. In a national survey of physicians, when doctors prescribed an advertised drug a patient had asked for, they reported that other drugs would have been equally effective 48% of the time — prescriptions written to accommodate patient demand generated by the advertising. Food products carry labels like "natural," "farm fresh," and "artisanal" that have no formal definition in FDA regulations — manufacturers apply them with almost no enforceable constraint. Native advertisements — paid content designed to look like journalism — were improperly disclosed by nearly 40% of publishers under FTC guidelines as of 2017; in a 2015 study of major news outlets, 80% of readers shown a sponsored post on the Wall Street Journal site and 71% on the New York Times site thought it was a journalistic article. Amazon blocked over 275 million suspected fake reviews in 2024 alone. UK internet providers advertised "up to" 20 or 24 Mbps speeds while delivering an average of 6.6 Mbps — roughly a third of the claimed speed — until regulators required ads to state average peak-time speeds from 2018.
George Akerlof's Nobel Prize-winning "Market for Lemons" analysis explains why this does not self-correct: when buyers cannot verify quality, sellers of good products cannot charge a premium, and the economic incentive shifts from producing quality to producing marketing. Producing transparent, unbiased product information is a public good that no individual firm has an incentive to provide. Advertising is a private good that directly benefits the advertiser. The structural result: over $1 trillion per year invested globally in persuasion, a fraction of that in accuracy. The competition is not between products. It is between marketing budgets.
After
You want to take better care of your health. You look up vitamin D and find the current scientific consensus: who benefits from supplementation, at what dosage, based on what evidence — presented clearly, without advertising, without competing claims, without commercial interest in the answer. If supplementation is beneficial for your situation, you access a supplement whose contents match its label, because no one benefits from putting rice flour in a vitamin bottle. If a healthy diet provides what you need, the information says so — because no one benefits from convincing you otherwise. The same applies to every diet, every treatment, every product: you search for information and find data compiled for accuracy, not persuasion.
Medical treatments are adopted based on comparative effectiveness — not on which manufacturer spent the most on television advertising. There are no "native ads" disguised as journalism, because there is no reason to disguise promotional messages as editorial content. There are no fake reviews, because no one has reason to manipulate others' decisions. The $1 trillion currently spent annually on global advertising — a sum larger than the GDP of all but about twenty countries — is not redirected somewhere else. It simply is no longer needed, because the function it claims to perform — helping people find what they need — is performed instead by transparent, searchable, scientifically grounded information systems that serve the people looking for answers rather than those promoting a product.